Protalix BioTherapeutics, Inc.PLXNYSE
LOADING
|||
Switch Symbol:
Gross Profit Growth Under Pressure
Trending lower, below historical average, structural decline.
Left:
||||
Year-over-year gross profit growth rate
Latest
-2.67%
↓ 101% below average
Average (39q)
200.93%
Historical baseline
Range
High:5985.88%
Low:-246.86%
CAGR
-11.0%
Structural decline
| Period | Value |
|---|---|
| Q3 2025 | -2.67% |
| Q2 2025 | 406.36% |
| Q1 2025 | -86.51% |
| Q4 2024 | 49.54% |
| Q3 2024 | 138.53% |
| Q2 2024 | 250.61% |
| Q1 2024 | -29.69% |
| Q4 2023 | -70.10% |
| Q3 2023 | -81.15% |
| Q2 2023 | 344.83% |
| Q1 2023 | 4.55% |
| Q4 2022 | -12.51% |
| Q3 2022 | 52.36% |
| Q2 2022 | -53.58% |
| Q1 2022 | 86.10% |
| Q4 2021 | -35.33% |
| Q3 2021 | 392.98% |
| Q2 2021 | -74.16% |
| Q1 2021 | -60.85% |
| Q4 2020 | 111.35% |
| Q3 2020 | -13.33% |
| Q2 2020 | -49.84% |
| Q1 2020 | 23.03% |
| Q4 2019 | 34.10% |
| Q3 2019 | 15.61% |
| Q2 2019 | 13.80% |
| Q1 2019 | -66.07% |
| Q4 2018 | 137.47% |
| Q3 2018 | 5985.88% |
| Q2 2018 | -110.87% |
| Q1 2018 | 78.03% |
| Q4 2017 | -37.33% |
| Q3 2017 | 74.85% |
| Q2 2017 | 4.24% |
| Q1 2017 | 520.93% |
| Q4 2016 | -69.43% |
| Q3 2016 | 348.94% |
| Q2 2016 | -39.74% |
| Q1 2016 | 103.04% |
| Q4 2015 | -246.86% |